Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
OncoZenge AB is a pharmaceutical company focusing on the development of specialized treatments targeting oncology. The primary purpose of OncoZenge AB is to innovate and deliver therapeutic solutions that address unmet medical needs in cancer care, particularly in the domain of mucositis and other cancer-related conditions. By concentrating its research efforts in these niche segments, OncoZenge aims to relieve patients of the side effects associated with cancer treatments, enhancing quality of life and overall treatment outcomes. OncoZenge AB operates within the broader healthcare industry, an essential sector that has a significant impact on enhancing global public health outcomes. It utilizes advanced biopharmaceutical methodologies, which integrate cutting-edge technology and research capabilities to push the boundaries of conventional cancer treatment. In the financial market, OncoZenge AB holds a specialized position owing to its commitment to addressing specific niche areas within oncology. Therefore, it plays a crucial role in the pharmaceutical landscape, contributing not only to innovative healthcare solutions but also to the comprehensive development of the oncology market.
kr 0.63
kr 0.01 (-1.09%)
Live · 11:12 PM · Twelve Data
The business is unprofitable at the operating level (-592.61% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -48.00% to -96.21%, capital efficiency is deteriorating. Negative free cash flow of -kr 13M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
-kr 49K
Net Income (TTM)
-kr 23M
▼ -83.5% YoY
Op. Margin
46189.80%
ROIC
-96.21%
▼ -48.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 21M
▼ -49.0% YoY
Op. Cash Flow (TTM)
-kr 21M
▼ -49.0% YoY
Net Debt
kr 4M
Cash & Equiv.
kr 4M
Continue Research
OncoZenge AB (ONCOZ.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, OncoZenge AB scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
OncoZenge AB scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 46,189.8% operating margin and a -96.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ONCOZ.XSTO's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.